Similarly, the homolog of ARID1A, ARID1B, is frequently mutated in endometrial cancer (9.7%) and in hepatocellular carcinoma (10.4%) (Table 3B) (115), but the abrogation mutation rate is <1%, which indicates that these are missense (i.e., silent) mutations which do not effect ARID1B expression. Here, ARID1B is linked to hepatocellular carcinoma.